Half-year report · HY
4272.TEDINET S100X0X1
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥113.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥222.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥109.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥10.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.8bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.7bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.6bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥391.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥373.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥356.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥122.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥269.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥268.5bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥264.2bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥68.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥55.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥71.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥52.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥18.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥25.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥75.07 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.17 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.21 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥75.07 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥107.16 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.2 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 68.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥113m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥113m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥4.9bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥34.4bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥34.2bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥106m |
| Fine Chemicals Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.0bn |
| Life Science Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Life Science Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Life Science Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6m |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥113.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥113.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥113m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥15.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.4bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥32.7bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥32.6bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Fine Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥109.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥109.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥15.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Removal loss of property plant and equipment inv cf | InterimDuration | -287000000 | JPY |
| Other net inv cf | Prior1InterimDuration | 50000000 | JPY |
| Other net inv cf | InterimDuration | 7000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -16490000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -2791000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1InterimDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | InterimDuration | 196000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | － | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 15000000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -2750000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -3606000000 | JPY |
| Purchase of treasury stock fin cf | Prior1InterimDuration | -3000000000 | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -9205000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -3721000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -5978000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1InterimDuration | -47000000 | JPY |
| Dividends paid to non controlling interests fin cf | InterimDuration | -62000000 | JPY |
| Other net fin cf | Prior1InterimDuration | -41000000 | JPY |
| Other net fin cf | InterimDuration | -35000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -9561000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -3691000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -1464000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 1430000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -12742000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 13235000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 64777000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 57926000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 52034000000 | JPY |
| Cash and cash equivalents | InterimInstant | 71161000000 | JPY |
| Payrolls selling expenses | Prior1InterimDuration | 3096000000 | JPY |
| Payrolls selling expenses | InterimDuration | 3205000000 | JPY |
| Bonuses and allowance sga | Prior1InterimDuration | 1012000000 | JPY |
| Bonuses and allowance sga | InterimDuration | 1065000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 102000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 68000000 | JPY |
| Depreciation sga | Prior1InterimDuration | 242000000 | JPY |
| Depreciation sga | InterimDuration | 201000000 | JPY |
| Payrolls general and administrative expenses | Prior1InterimDuration | 2362000000 | JPY |
| Payrolls general and administrative expenses | InterimDuration | 2530000000 | JPY |
| Bonuses and allowance general and administrative expenses | Prior1InterimDuration | 509000000 | JPY |
| Bonuses and allowance general and administrative expenses | InterimDuration | 579000000 | JPY |
| Retirement benefit expenses ga | Prior1InterimDuration | 90000000 | JPY |
| Retirement benefit expenses ga | InterimDuration | 61000000 | JPY |
| Depreciation ga | Prior1InterimDuration | 381000000 | JPY |
| Depreciation ga | InterimDuration | 574000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 6327000000 | JPY |
| Research and development expenses sga | InterimDuration | 4958000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 45996000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 32618000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30495000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |